Deals
UCB Paid $1.15B for Neurona's Single-Dose Epilepsy Cell Therapy
UCB paid up to $650m upfront, with up to $500m in future milestones, to buy Neurona Therapeutics in a deal valued at up to $1.15bn.
Tag
Eli Lilly
21 stories
Legal
Revived: $176.5M Patent Verdict Leaves Lilly to Evaluate Options
The Court of Appeals for the Federal Circuit on Thursday reinstated the $176.5 million verdict that Teva won in 2022, reviving its claim that Eli Lilly's…
Deals
Kailera Prices $625m IPO, One of the Largest Biotech Offerings Since Moderna 2018
Kailera Therapeutics priced its IPO at $625m, or $16 a share, on April 16 — at the top of its S-1 range and one of the largest biotech public offerings…
Deals
Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018
Kailera Therapeutics priced its IPO at $16 a share Friday, raising $625 million, the largest biotech public offering in recent memory, topping Moderna's…
Deals
Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total
Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year's full-year total of $20.3 billion with three…
FDA
FDA Cleared Foundayo With 3 Postmarketing Safety Study Requirements
FDA cleared Foundayo, Eli Lilly's oral GLP-1 pill for obesity, on April 1, but the approval letter lists three postmarketing requirements tied to what the…
FDA
Beats Venetoclax: Lilly's Jaypirca Posts 4th Phase 3 Win in CLL
Jaypirca chalked up its fourth positive phase 3 readout in chronic lymphocytic leukemia on Monday, and this one rewrites the treatment calculus: it's the…
Deals
AbbVie Bought Two NaV1.8 Pain Assets from Haisco for $745M
AbbVie bought ex-China rights to two NaV1.8 sodium channel pain inhibitors from Beijing-based Haisco Pharmaceutical for up to $745 million.
Deals
Kailera Files $528.5M Nasdaq IPO to Fund Four GLP-1 Obesity Drugs
Kailera filed for a $528.5 million Nasdaq IPO, pricing 33.33 million shares at $14 to $16 each.
Deals
Regeneron Paid $40M to Enter Radiopharma; Telix Scores Up to $4.3B
Regeneron put $40 million on the table Sunday to partner with Telix Pharmaceuticals, the Australian biotech with one of the more active radiopharmaceutical…
Deals
AbbVie Buys Into Pain With Up to $715M Haisco Deal
AbbVie is paying up to $715 million to get into the pain game, inking a licensing deal with China's Haisco Pharmaceutical Group that hands AbbVie rights to…
FDA
FDA Cleared Foundayo; Lilly Pre-Stocked $1.5B Before Approval
FDA cleared Foundayo eight days ago, and Eli Lilly was ready: the company pre-stocked $1.5 billion worth of the pill back in February, months before…
FDA
Lilly's Foundayo Clears FDA; Novo's Oral Wegovy Holds 5-Point Efficacy Lead
Lilly's oral obesity pill approved but trails Novo on weight loss. Pharma's M&A sprint added $7.9B in deals and Trump's tariffs landed with carveouts.
Deals
Eli Lilly Bets on Orexins — Same Playbook That Made Tirzepatide a Blockbuster
Eli Lilly acquires into the orexin drug class, betting the maturing CNS mechanism follows the same multi-indication arc as GLP-1.
FDA
Novo Nordisk's 7.2 mg Wegovy Hits US Shelves at Triple the Standard Dose
Novo Nordisk's 7.2 mg Wegovy is now available in the US, tripling the standard 2.4 mg dose in a direct bid to reclaim ground lost to Lilly's Zepbound.
Deals
Lilly Pays $7.8B for Centessa to Buy Into the Orexin Race
Lilly is paying $7.8B for Centessa — $38/share plus a $9 CVR — to grab cleminorexton, a Phase IIa orexin agonist for narcolepsy.
deals
Deals
Anthropic Pays $400M for a 10-Person Ghost Company
Anthropic is paying ~$400M for Coefficient Bio, a sub-10-person stealth startup. The price signals how expensive life sciences AI talent has become.
FDA
Novo Fires Back at Lilly's Foundayo With Competing Efficacy Data
Novo Nordisk published rival efficacy data the day after FDA approved Lilly's oral obesity pill Foundayo — but no head-to-head trial exists to back the claims.
Deals
Lilly Pays $115M Upfront in Insilico AI Deal Worth Up to $2.75B
Eli Lilly paid $115M upfront for an AI collaboration with Insilico Medicine worth up to $2.75B, with milestone math that heavily favors Lilly.
FDA
FDA Clears 7.2mg Wegovy HD for Novo Nordisk in 54-Day Sprint
FDA cleared Novo Nordisk's 7.2mg Wegovy HD in 54 days under its national priority program, pushing the GLP-1's efficacy ceiling higher.
FDA
Lilly's Oral GLP-1 Pill Cleared in 50 Days, Fastest NME Since 2002
Eli Lilly's oral GLP-1 pill orforglipron approved in 50 days under the FDA's CNPV pilot — the fastest new molecular entity approval since 2002.
